Despite a beat on both top and bottom lines with its Q3 2024 financials, Regeneron Pharmaceuticals (NASDAQ:REGN) lost more than 10% on Thursday, a move BMO Capital Markets attributed to lower-than-expected sales from its up-and-coming eye medicine, high-dose Eylea.

The